Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hartley

Showing results (401-410 of 451) with videos related to

Pageof 46
Sort By:
Journal of Alzheimer'S Disease : JAD|December 24, 2022
Weight Loss and Alzheimer's Disease in Down SyndromeVictoria Fleming, Brian C Helsel, Lauren T Ptomey, et al.
The Lancet. Neurology|November 22, 2024
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort studyEmily K Schworer, Matthew D Zammit, Jiebiao Wang, et al.
Neuroimage|January 9, 2021
PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndromeMatthew D Zammit, Dana L Tudorascu, Charles M Laymon, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 25, 2021
Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamenMatthew D Zammit, Charles M Laymon, Dana L Tudorascu, et al.
Cancer Chemotherapy and Pharmacology|September 28, 2012
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapyMichael J Pishvaian, Rebecca Slack, Eunice Y Koh, et al.
Molecular & Cellular Proteomics : MCP|August 23, 2005
Pooled ORF expression technology (POET): using proteomics to screen pools of open reading frames for protein expressionWilliam K Gillette, Dominic Esposito, Peter H Frank, et al.
Medrxiv : the Preprint Server for Health Sciences|August 30, 2024
Amyloid age and tau PET timeline to symptomatic Alzheimer's disease in Down syndromeEmily K Schworer, Matthew D Zammit, Jiebiao Wang, et al.
Current Biology : CB|June 9, 1999
Suckling defect in mice lacking the soluble haemopoietin receptor NR6W S Alexander, S Rakar, L Robb, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2006
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signalingMasaya Baba, Seung-Beom Hong, Nirmala Sharma, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|April 7, 2022
Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal studyConcepcion Padilla, Victor Montal, Madeleine J Walpert, et al.
Pageof 46

Showing results (401-410 of 451) with videos related to

Sort By:
Pageof 46
Journal of Alzheimer'S Disease : JAD|December 24, 2022
Weight Loss and Alzheimer's Disease in Down SyndromeVictoria Fleming, Brian C Helsel, Lauren T Ptomey, et al.
The Lancet. Neurology|November 22, 2024
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort studyEmily K Schworer, Matthew D Zammit, Jiebiao Wang, et al.
Neuroimage|January 9, 2021
PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndromeMatthew D Zammit, Dana L Tudorascu, Charles M Laymon, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|January 25, 2021
Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamenMatthew D Zammit, Charles M Laymon, Dana L Tudorascu, et al.
Cancer Chemotherapy and Pharmacology|September 28, 2012
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapyMichael J Pishvaian, Rebecca Slack, Eunice Y Koh, et al.
Molecular & Cellular Proteomics : MCP|August 23, 2005
Pooled ORF expression technology (POET): using proteomics to screen pools of open reading frames for protein expressionWilliam K Gillette, Dominic Esposito, Peter H Frank, et al.
Medrxiv : the Preprint Server for Health Sciences|August 30, 2024
Amyloid age and tau PET timeline to symptomatic Alzheimer's disease in Down syndromeEmily K Schworer, Matthew D Zammit, Jiebiao Wang, et al.
Current Biology : CB|June 9, 1999
Suckling defect in mice lacking the soluble haemopoietin receptor NR6W S Alexander, S Rakar, L Robb, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2006
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signalingMasaya Baba, Seung-Beom Hong, Nirmala Sharma, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|April 7, 2022
Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal studyConcepcion Padilla, Victor Montal, Madeleine J Walpert, et al.
Pageof 46